PP_1170x120_10-25-21

COVID-19 pandemic response

Phlow Corp. awarded $354 million HHS/ASPR/BARDA contract for COVID-19 response

Phlow Corp. awarded $354 million HHS/ASPR/BARDA contract for COVID-19 response

RICHMOND,  Va. – Phlow, a U.S.-based, public benefit drug manufacturing corporation, has received federal government funding of $354 million for advanced manufacturing of America’s most essential medicines at risk of shortage, including medicines for the COVID-19 pandemic response. This project has been funded with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), part